Meeting Program

6:45 AM — 6:35 PM

Exhibits Open

6:45 AM — 8:00 AM

Continental Breakfast Provided

8:00 AM — 8:15 PM

Welcome

8:15 AM — 9:45 AM

General Session I: Prostate Cancer: Active Surveillance and Screening

Chairs: Mack Roach III, MD - University of California, San Francisco; Hans T. Chung, MD - Toronto-Sunnybrook Reg Cancer Centre

• Understanding the US Preventative Task Force Recommendations on PSA Screening
  Ian Thompson, MD - University of Texas Health Science Center at San Antonio
   
• What is the Current Status of Active Surveillance?
  Chris Parker, MD, MRCP - The Institute for Cancer Research and Royal Marsden Hospital
   
• What Tools Are Available to Aid in the Use of Active Surveillance?
  Imaging:           Peter L. Choyke, MD -  CCR, NCI, NIH
  Biomarkers:    Matthew Cooperberg, MD, MPH - University of California,    San Francisco
  Pathology:       Jesse McKenney, MD - Stanford University Medical Center
  
  
• Abstract #1: Gleason upgrading with time in a large, active surveillance cohort with long-term follow-up.
  Presenting Author: Suneil Jain
  
  

9:45 AM — 10:15 AM

Break

10:15 AM — 11:45 AM

General Session II: Translational Science: Prostate Cancer

Chairs: Daniel W. Lin, MD - University of Washington; Felix Feng, MD - University of Michigan Medical Center   

• Alternative DHT Synthesis as a Driver of Castration-resistant Prostate Cancer and the Impact Resistance/Escape from CYP17 Inhibitors
  Nima Sharifi, MD - University of Texas Southwestern Medical Center
   
• Novel Strategies for Targeting the Androgen Receptor Axis
  Karen Knudsen, PhD – Kimmel Cancer Center, Thomas Jefferson University
   
• Practical Challenges in Precision Medicine in Prostate Cancer
  Ken Pienta, MD – University of Michigan Medical Center
  
  
• Abstract #2: Associations between single nucleotide polymorphisms (SNPs) in inflammation-related genes and quality of life after radiation therapy (RT) for prostate cancer.
  Presenting Author: Jonathan Schoenfeld

11:45 AM — 1:15 PM

General Poster Session A: Prostate Cancer

(with complimentary boxed lunch)

1:15 PM — 3:05 PM

Oral Abstract Session A: Prostate Cancer†

Chairs: David Bottomley, MBBS - The Leeds Teaching Hospitals; Paul Nguyen, MD – Dana-Farber Cancer Institute

• Abstract #3: High-risk prostate cancer treated with pelvic radiotherapy and 36 versus18 months of androgen blockade: Results of a phase III randomized study. 
  Presenting Author: Abdenour Nabid, MD, FRCP(C)
  
  
• Abstract #4: Phase III results of adjuvant radiotherapy (RT) versus wait-and-see (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP)(ARO 96-02/AUO AP 09/95): Ten years follow-up.
  Presenting Author: Thomas Wiegel, MD
  
  
• Discussion (Abstracts #3 and #4)
  Anthony D’Amico, MD, PhD – Dana-Farber Cancer Institute/Brigham and Women's Hospital
  
  
• Abstract #5: Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy.
  Presenting Author: Dana Rathkopf, MD
  
  
• Abstract #6: Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor.
  Presenting Author: Howard Scher, MD
  
  
• Abstract #7: ARN-509 in men with high-risk nonmetastatic castration-resistant prostate cancer (CRPC).
  Presenting Author: Matthew Smith, MD, PhD
  
  
• Abstract #13: Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): Results from the multinational phase III trial (VENICE).
  Presenting Author: Ian Tannock, MD
  
  
• LBA #8: Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the phase III READY trial.
  Presenting Author: John Araujo, MD, PhD
  
  
• Discussion (Abstracts #5-7; 13)
  William Oh, MD - Tisch Cancer Institute, Mount Sinai School of Medicine

3:05 PM — 3:35 PM

Break

3:35 PM — 5:05 PM

General Session III: Prostate Cancer*

Chairs: William L. Dahut, MD - National Cancer Institute, National Institutes of Health;
Karen E. Hoffman, MD, MHSc, MPH - University of Texas M. D. Anderson Cancer Center

• Clinical Strategies to Overcome Androgen Resistance 
  Charles J. Ryan, MD - University of California, San Francisco
   
• State of the Art: Imaging in Prostate Cancer
  Steve Larson, MD - Memorial Sloan-Kettering Cancer Center
   
• Challenging Cases
  Radiation Oncologist: Daniel A. Hamstra, MD, PhD, University of Michigan Medical Center
  
  Medical Oncologist: Evan Y. Yu, MD – University of Washington Fred Hutchinson Cancer Research Center
  
  Urologist: Peter A. Pinto, MD - National Cancer Institute, National Institutes of Health
  
  Radiologist: Peter L. Choyke, MD - Molecular Imaging Program, CCR, NCI, NIH

5:05 PM — 6:35 PM

General Poster Session A, Continued: Prostate Cancer

(with complimentary wine and cheese reception)

5:20 PM — 6:35 PM

Fellows Poster Walk: Prostate Cancer (ticketed)

(Attendance limited to Fellows, Residents, and Junior Faculty)

James Gulley, MD - Center for Cancer Research, National Cancer Institute
Jason Efstathiou, MD, DPhil - Massachusetts General Hospital
 

6:45 AM — 6:45 PM

Exhibits Open

6:45 AM — 7:55 AM

Continental Breakfast Provided

7:00 AM — 7:45 AM

Best of Journals: Prostate cancer

• Urologist: Eric A. Singer, MD, MA - National Cancer Institute, National Institutes of Health
  
  

• Radiation Oncologist: Paul Linh Nguyen, MD - Dana-Farber Cancer Institute/Brigham and Women's Hospital
  
  
• Medical Oncologist: Ravi Madan, MD - National Cancer Institute, National Institutes of Health

7:55 AM — 8:00 AM

Welcome

8:00 AM — 9:30 AM

General Session IV: Urothelial Carcinomas: Multimodal Management of Difficult Cases*

Chairs: Ashish M. Kamat, MD - University of Texas M. D. Anderson Cancer Center; Andrea B. Apolo, MD - National Cancer Institute

• State of the Art: Targeted Therapy for Low-Grade but Rapidly-Recurring NMI Tumors
  Bas W.G. Van Rhijn, MD, PhD -University Health Network, Princess Margaret Hospital
  
  
• State of the Art: Role of the Radiation Oncologist in High-Risk NMIBC
  Justin E. Bekelman, MD - University of Pennsylvania Abramson Cancer Center
  
  
• State of the Art: Immunotherapy for Localized Urothelial Cancer: Moving Beyond BCG
  Padmanee Sharma, MD, PhD - University of Texas M. D. Anderson Cancer Center
  
  
• Panel Discussion
  Medical Oncologist: Padmanee Sharma, MD, PhD - M. D. Anderson Cancer Center
  Urologist: Bas W.G. Van Rhijn, MD, PhD -University Health Network, Princess Margaret Hospital
  Pathologist: Charles Guo, MD - University of Texas M. D. Anderson Cancer Center
  Radiation Oncologist: Nicholas James, MD, PhD - University of Birmingham
  
  
• Abstract #246: Novel definition of BCG failure to enhance recruitment into clinical trials.
  Presenting Author: Daniel Willis, MD

9:30 AM — 10:00 AM

Break

10:00 AM — 10:45 AM

Keynote Lecture

Personalized Medicine
Arul Chinnaiyan, MD, PhD - University of Michigan

10:45 AM — 12:15 PM

General Session V: Translational Science Session: Urothelial Carcinomas

Chairs: Peter Carroll, MD, MPH - University of California, San Francisco; Theresa Koppie, MD - University of California, Davis

• Gene Expression and Mutation: Prognostic Biomarkers in Urothelial Cancer
  Dan Theodorescu, MD, PhD - University of Colorado
  
  
• Gene Expression Guided Therapy for Urothelial Cancers
  Randall E. Millikan, MD, PhD - University of Texas M. D. Anderson Cancer Center
  
  
• RTOG Clinical Trial Updates
  Douglas Dahl, MD - Massachusetts General Hospital
  
  
• Surgical Quality and Outcomes of Urologic Cancer Care
  Seth Strope, MD, MPH - Washington University School of Medicine
  
  
  
• Abstract # 247: Genomic characterization of metastatic urothelial carcinoma.
  Presenting Author: Richard Bambury, MB
  
  

12:15 PM — 1:45 PM

General Poster Session B: Prostate, Penile, Urethral, and Testicular Cancer, and urothelial carcinoma

with Complimentary Boxed Lunch Provided

12:30 PM — 1:45 PM

Fellows, Residents, and Junior Faculty Networking Luncheon (Ticketed)

 Chair: Christopher Sweeney, MBBS - Dana-Farber Cancer Institute

1:45 PM — 3:15 PM

Oral Abstract Session B: urothelial carcinoma and testicular cancer†

Chairs: Sia Daneshmand, MD – University of Southern California; Matthew Milowsky, MD - Memorial Sloan-Kettering Cancer Center

• Abstract #319: Prediction of relapse in stage I nonseminomatous germ cell tumors (NSGCT) by CXCL12: Results from the MRC TE08 and TE22 clinical trials.
  Presenting Author: Duncan Charles Gilbert, MBBS PhD
  
  
• Abstract #320: Cost analysis of adjuvant management strategies in early-stage testicular seminoma.
  Presenting Author: John A. Cox, MD
  
  
• Abstract #248: Clinical-pathologic stage discrepancy in patients with bladder cancer treated with radical cystectomy: Associations with clinical variables and survival. 
  Presenting Author: Phillip Gray, MD
  
  
• Abstract #249: Randomized phase III trial of neoadjuvant chemotherapy (NAC) with methotrexate, doxorubicin, vinblastine, and cisplatin (MVAC) followed by radical cystectomy (RC) compared with RC alone for invasive bladder cancer (BC): Japan Clinical Oncology Group Study, JCOG0209.
  Presenting Author: Hiroshi Kitamura, MD, PhD
  
  
• Abstract #250: Randomized phase III study of adjuvant versus progression-triggered treatment with gemcitabine (G) after radical cystectomy (RC) for locally advanced bladder cancer (LABC) in patients not suitable for cisplatin-based chemotherapy (CBC) (AUO-trial AB22/00). 
  Presenting Author: Jan Lehmann, MD
  
  
• Discussion: The Future of Biomarker-Driven Therapeutics
  Dean Bajorin, MD – Memorial Sloan- Kettering Cancer Center
  
  

3:15 PM — 3:45 PM

Break

3:45 PM — 5:15 PM

General Session VI: Penile, urethral, and testicular Cancers

Chairs: Mark K. Buyyounouski, MD, MS - Fox Chase Cancer Center; Yohann Loriot, MD - Institut Gustave-Roussy

• Rare Testicular Cancers
  Stephane Culine, MD, PhD
  
  
• Urethral Carcinomas
  Curtis Pettaway, MD - The University of Texas MD Anderson Cancer Center
  
  
• Management of Relapsed Stage-I Seminoma
  Padraig R. Warde, MD - Princess Margaret Hospital and University of Toronto
  
  
• The Role of Adjuvant Radiation Therapy in Locally Advanced Penile Cancer
  Clair Beard, MD - Dana-Farber Cancer Institute
  
  
• Shall We Simply Respect the Rules to Maximize Cure Rates in Testicular Cancer?
  Craig R. Nichols, MD - Virginia Mason Medical Center

5:15 PM — 6:45 PM

General Poster Session b, continued: prostate, Penile, Urethral, and Testicular Cancers, and urothelial carcinoma

(with complimentary wine and cheese reception)  
 

5:30 PM — 6:45 PM

Fellows Poster Walk: prostate, Penile, Urethral, and Testicular Cancers, and urothelial carcinoma (ticketed)

(Attendance limited to Fellows, Residents, and Junior Faculty)

Max Meng, MD - University of California, San Francisco (Urothelial Carcinoma)

Noah Hahn, MD - University of Indiana Simon Cancer Center (Penile, Urethral, and Testicular Cancer)
 

6:45 AM — 7:55 AM

General Poster Session c: Renal Cancer

(with complimentary continental breakfast)

7:00 AM — 7:45 AM

Best of Journals: Renal Cancer

• Translational: Edwin J. Abel, MD - University of Wisconsin School of Medicine
• Urologist: David Chen, MD - Fox Chase Cancer Center
• Medical Oncologist: Lauren Harshman, MD - Stanford University School of Medicine

7:55 AM — 8:00 AM

Welcome

8:00 AM — 9:30 AM

General Session VII: Translational Science Session: Renal Cancer

Chairs: Hyung L. Kim, MD - Cedar-Sinai Medical Center; Elizabeth R. Plimack, MD, MS - Fox Chase Cancer Center

• Biomarker Development as a Parallel to Drug Development
  Richard Simon, DSc - National Cancer Institute
  
  
• Metabolomics in Kidney Cancer
  Robert Weiss, MD - University of California, Davis
  
  
• Permissiveness/Redundancy of the VEGF Pathway: Why Better VEGF-TKIs Don't Translate into Better Clinical Therapies
  Robert Figlin, MD - Cedars-Sinai Samuel Oschin Comprehensive Cancer Center
  
  
• "Radiogenomics" of Renal Cell Carcinoma
  Oguz Akin, MD - Memorial Sloan-Kettering Cancer Center
  
  
• Developing Strategies: Immunotherapies and PD1 Inhibition
  David McDermott, MD - Beth Israel Deaconess Medical Center
  
  
• Abstract #341: Toward a molecular genetic classification of clear cell renal cell carcinoma.
  Presenting Author: James Brugarolas, MD, PhD

9:30 AM — 10:00 AM

Break

10:00 AM — 11:50 PM

Oral Abstract Session C: Renal Cancer†

Chairs: Robert Uzzo, MD – Fox Chase Cancer Center; Sumanta Pal, MD -  City of Hope

• Abstract #342: Defining early-onset kidney cancer: Implications for genetic counseling.
  Presenting Author: Brian Shuch, MD
  
  
• Abstract #343: Surveillance for the management of small renal masses: Utilization and outcomes in a population-based cohort.
  Presenting Author: William C. Huang, MD
  
  
• Abstract #344: Outcomes, complications, and costs of care of Bosniak IIF, III, and IV cystic renal lesions/malignancies: Data from the largest multi-institutional study to date.
  Presenting Author: Andrew D. Smith, MD, PhD
  
  
• Abstract #345: The best trial (E2804): A randomized phase II study of VEGF, RAF kinase, and mTor combination targeted therapy (CTT) with bevacizumab (bev), sorafenib (sor), and temsirolimus (tem) in advanced renal cell carcinoma (RCC).  
  Presenting Author: David F. McDermott, MD
  
  
• Abstract #346: Quality of life (QoL) among patients with renal cell carcinoma (RCC) treated with pazopanib versus sunitinib in the COMPARZ study.
  Presenting Author: David Cella, PhD
  
  
• Abstract #347: Incidence and risk of treatment-related mortality in patients with renal cell cancer (RCC) and non-RCC treated with mammalian target of rapamycin (mTOR) inhibitors.
  Presenting Author: Toni K. Choueiri, MD
  
  
• LBA #348: Axitinib versus sorafenib as first‑line therapy in patients with metastatic renal cell carcinoma: Results from a phase III randomized trial.
  Presenting Author: Thomas E. Huston, DO, PharmD
  
  
• Discussion (Abstracts #345-347)
  Sandy Srinivas, MD -  Stanford University

11:50 AM — 1:05 PM

General Poster Session c, continued: Renal Cancer

(with complimentary boxed lunch)

1:05 PM — 2:35 PM

General Session VIII: Renal Cancer

Chairs: Robert G. Uzzo, MD - Fox Chase Cancer Center; Brian R. Lane, MD, PhD - Spectrum Health, Michigan State University

• Radical or Partial Nephrectomy for Localized Disease in the Elderly
  Partial: John Gore, MD, MD - University of Washington School of Medicine
  Radical: Alexander Kutikov, MD - Fox Chase Cancer Center
  
  
• The Perils of Using Large Population-based Data Sets to Answer Clinically Relevant Kidney Cancer Questions
  Brent Hollenbeck, MD - University of Michigan
  
  
• Measuring Kidney Cancer Risk Prior to the Operating Room
  Nomograms and Preoperative Risk Models: Michael Kattan, PhD - Cleveland Clinic
  Can Imaging Predict HIstology?: Raghu Vikram, MD - University of Texas M. D. Anderson Cancer Center
  Performance of Renal Mass Biopsy in Risk Stratification: Stuart Silverman, MD - Brigham and Women's Hospital
  
  
• Dose Intensity, Imaging, and Best Supportive Care
  Objectifying Imaging Changes Post-TKI's: Shetal Shah, MD - Cleveland Clinic
  How Important is Dose Intensity and When is Dose Reduction the Better Strategy?: Brian Rini, MD - Cleveland Clinic
  Best Supportive Care: Peg Esper, MSN, RN, CS, AOCN - University of Michigan 

Click here for information on registering for ticketed sessions.
* -- Indicates use of the Audience Response System (ARS) technology
†-- Indicates use of the electronic Q&A system (eQ&A)